In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Carisma Therapeutics Inc (NASDAQ: CARM) closed at $0.4 in the last session, up 0.50% from day before closing price of $0.4. In other words, the price has increased by $0.50 from its previous closing price. On the day, 0.56 million shares were traded. CARM stock price reached its highest trading level at $0.41 during the session, while it also had its lowest trading level at $0.39.
Ratios:
We take a closer look at CARM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.34 and its Current Ratio is at 1.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on December 12, 2024, Downgraded its rating to Neutral and sets its target price to $1 from $10 previously.
On April 11, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $6.BTIG Research initiated its Buy rating on April 11, 2024, with a $6 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CARM now has a Market Capitalization of 16715240 and an Enterprise Value of 10104218. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.84. Its current Enterprise Value per Revenue stands at 0.506 whereas that against EBITDA is -0.212.
Stock Price History:
The Beta on a monthly basis for CARM is 1.86, which has changed by -0.6825397 over the last 52 weeks, in comparison to a change of 0.1116153 over the same period for the S&P500. Over the past 52 weeks, CARM has reached a high of $1.38, while it has fallen to a 52-week low of $0.14. The 50-Day Moving Average of the stock is 27.14%, while the 200-Day Moving Average is calculated to be -23.83%.
Shares Statistics:
According to the various share statistics, CARM traded on average about 14.49M shares per day over the past 3-months and 700080 shares per day over the past 10 days. A total of 41.79M shares are outstanding, with a floating share count of 21.12M. Insiders hold about 49.46% of the company’s shares, while institutions hold 8.14% stake in the company. Shares short for CARM as of 1749772800 were 3104821 with a Short Ratio of 0.07, compared to 1747267200 on 841044. Therefore, it implies a Short% of Shares Outstanding of 3104821 and a Short% of Float of 8.459999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Carisma Therapeutics Inc (CARM) is currently drawing attention from 1.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.41 and -$0.41 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.66, with 1.0 analysts recommending between -$0.66 and -$0.66.
Revenue Estimates
According to 1 analysts, the current quarter’s revenue is expected to be $3.75M. It ranges from a high estimate of $3.75M to a low estimate of $3.75M. As of the current estimate, Carisma Therapeutics Inc’s year-ago sales were $9.2MFor the next quarter, 1 analysts are estimating revenue of $3.75M. There is a high estimate of $3.75M for the next quarter, whereas the lowest estimate is $3.75M.
A total of 1 analysts have provided revenue estimates for CARM’s current fiscal year. The highest revenue estimate was $15M, while the lowest revenue estimate was $15M, resulting in an average revenue estimate of $15M. In the same quarter a year ago, actual revenue was $19.63M
